• Danny Dvir, John G Webb, Sabine Bleiziffer, Miralem Pasic, Ron Waksman, Susheel Kodali, Marco Barbanti, Azeem Latib, Ulrich Schaefer, Josep Rodés-Cabau, Hendrik Treede, Nicolo Piazza, David Hildick-Smith, Dominique Himbert, Thomas Walther, Christian Hengstenberg, Henrik Nissen, Raffi Bekeredjian, Patrizia Presbitero, Enrico Ferrari, Amit Segev, Arend de Weger, Stephan Windecker, Neil E Moat, Massimo Napodano, Manuel Wilbring, Alfredo G Cerillo, Stephen Brecker, Didier Tchetche, Thierry Lefèvre, Federico De Marco, Claudia Fiorina, Anna Sonia Petronio, Rui C Teles, Luca Testa, Jean-Claude Laborde, Martin B Leon, Ran Kornowski, and Valve-in-Valve International Data Registry Investigators.
• St Paul's Hospital, Vancouver, British Columbia, Canada.
• JAMA. 2014 Jul 1; 312 (2): 162-70.

ImportanceOwing to a considerable shift toward bioprosthesis implantation rather than mechanical valves, it is expected that patients will increasingly present with degenerated bioprostheses in the next few years. Transcatheter aortic valve-in-valve implantation is a less invasive approach for patients with structural valve deterioration; however, a comprehensive evaluation of survival after the procedure has not yet been performed.ObjectiveTo determine the survival of patients after transcatheter valve-in-valve implantation inside failed surgical bioprosthetic valves.Design, Setting, And ParticipantsCorrelates for survival were evaluated using a multinational valve-in-valve registry that included 459 patients with degenerated bioprosthetic valves undergoing valve-in-valve implantation between 2007 and May 2013 in 55 centers (mean age, 77.6 [SD, 9.8] years; 56% men; median Society of Thoracic Surgeons mortality prediction score, 9.8% [interquartile range, 7.7%-16%]). Surgical valves were classified as small (≤21 mm; 29.7%), intermediate (>21 and <25 mm; 39.3%), and large (≥25 mm; 31%). Implanted devices included both balloon- and self-expandable valves.Main Outcomes And MeasuresSurvival, stroke, and New York Heart Association functional class.ResultsModes of bioprosthesis failure were stenosis (n = 181 [39.4%]), regurgitation (n = 139 [30.3%]), and combined (n = 139 [30.3%]). The stenosis group had a higher percentage of small valves (37% vs 20.9% and 26.6% in the regurgitation and combined groups, respectively; P = .005). Within 1 month following valve-in-valve implantation, 35 (7.6%) patients died, 8 (1.7%) had major stroke, and 313 (92.6%) of surviving patients had good functional status (New York Heart Association class I/II). The overall 1-year Kaplan-Meier survival rate was 83.2% (95% CI, 80.8%-84.7%; 62 death events; 228 survivors). Patients in the stenosis group had worse 1-year survival (76.6%; 95% CI, 68.9%-83.1%; 34 deaths; 86 survivors) in comparison with the regurgitation group (91.2%; 95% CI, 85.7%-96.7%; 10 deaths; 76 survivors) and the combined group (83.9%; 95% CI, 76.8%-91%; 18 deaths; 66 survivors) (P = .01). Similarly, patients with small valves had worse 1-year survival (74.8% [95% CI, 66.2%-83.4%]; 27 deaths; 57 survivors) vs with intermediate-sized valves (81.8%; 95% CI, 75.3%-88.3%; 26 deaths; 92 survivors) and with large valves (93.3%; 95% CI, 85.7%-96.7%; 7 deaths; 73 survivors) (P = .001). Factors associated with mortality within 1 year included having small surgical bioprosthesis (≤21 mm; hazard ratio, 2.04; 95% CI, 1.14-3.67; P = .02) and baseline stenosis (vs regurgitation; hazard ratio, 3.07; 95% CI, 1.33-7.08; P = .008).Conclusions And RelevanceIn this registry of patients who underwent transcatheter valve-in-valve implantation for degenerated bioprosthetic aortic valves, overall 1-year survival was 83.2%. Survival was lower among patients with small bioprostheses and those with predominant surgical valve stenosis.

22 keywords...

hide…